HAYA Therapeutics doses first cohort in Phase I HTX-001 trial
HAYA Therapeutics co-founder and CSO Daniel Blessing led HTX-001 research and development from concept to clinical trial.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance